Researchers presented efficacy and ongoing safety data from MonumenTAL-1, a phase 1/2 study assessing talquetamab in patients with multiple myeloma.

The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...

CAPTEM (capecitabine and temozolomide) provided a high rate of disease control in patients with typical and atypical lung ...

A retrospective study found an association between elevated ALC and CAR+ T-cell counts and development of neurologic events in patients with r/r MM.

New research suggests that, among patients with neuroendocrine tumors, primary tumor sites differ by race, and overall survival outcomes differ by tumor site and gender.

Real-world study confirmed that longer platinum-free interval was associated with better survival and prolonged 2L treatment duration in pts with endometrial cancer.

Results of CheckMate 67T, a phase 3 noninferiority study comparing subcutaneous and intravenous nivolumab formulations in RCC, were presented at JADPRO 2025.

From 2003 to 2017, cancer incidence rates increased for several cancer types, with increases in younger and older adults for many cancers, according to a study.

PRRT retreatment may be well tolerated and confer a survival benefit in patients with well-differentiated, metastatic neuroendocrine tumors, a study suggests.